14.11.2022 | Tracker

Product Launch Tracker: HCPs share optimism for approvals in heart failure, obesity and multiple myeloma

By Paul Cranston and Tomi Shobande

Every month, CREATION.co’s tracking updates bring you the latest insights from the conversation of healthcare professionals (HCPs) across the globe discussing product launches. Discover which new drug approvals HCPs are talking about, what they think about them, and which online sources they are using to inform their opinions and conversations in CREATION.co’s latest tracking update.


Throughout October 2022 we tracked the global conversations of 1,830 HCPs who posted 2,527 English-language Twitter posts about the launches and approvals of new products.

Across the month of October, HCPs commented on and shared the news of many new product approvals across various indications including obesity, multiple myeloma, heart failure and COVID-19. 

At the start of the month, HCPs shared the news of Eli Lilly receiving fast track designation for Mounjaro (tirzepatide) for the treatment of adults with obesity. HCPs held the treatment in high regard, claiming the drug to be ‘remarkably effective’ and to have a significant long term benefit to many patients’ cardiometabolic health..

HCPs also discussed the FDA’s approval of Janssen’s Tecvayli (teclistimab) for the treatment of adult patients with relapsed or refractory multiple myeloma. The treatment is indicated for patients who received four or more previous lines of therapy. Based on the response rate from a trial, the regulatory agency approved the indication under an accelerated approval process. HCPs declared the approval to be ‘wonderful news’ for patients and an ‘important new option’ for treating multiple myeloma.

Another product HCPs discussed online, to gain FDA approval is scPharmaceuticals’ Furoscix, a self-administered subcutaneous injection of furosemide for the treatment of congestion from fluid overload in adults with chronic heart failure. It is the first home treatment which can support patients with worsening congestion who show a decreased responsiveness to other treatments, which usually necessitates hospital admission. Many cardiologists came together to discuss the usefulness of the novel product, with some showing positive sentiments about its potential to keep patients out of hospital, while others were more cautious, primarily due to cost effectiveness and the dose limit of the treatment.

In relation to COVID-19, HCPs shared the news of the EMA recommending granting an extension of indication for the COVID-19 vaccine Comirnaty and Spikevax targeting the original strain of SARS-Cov-2. The Committee recommended including the use of in children aged 6 months to 4 years for Comirnaty and use in children aged 6 months to 5 years for Spikevax. Comirnaty and Spikevax are already approved in both adults and children aged from 5 and 6 years, respectively. HCPs predominantly chose to distribute this news from the EU Medicines agency’s official account rather than individually commenting on the approval.

Shared by 18 HCPs

The three most shared links from HCPs discussing product launches in June were:

Each month, CREATION.co tracks the HCP conversation relating to new product launches.

You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up to CREATION.co’s monthly eJournal.


  • Using CREATION Pinpoint® the English-language Twitter conversations of HCPs globally discussing new pharmaceutical product launches and drug approvals between 1 October and 31 October 2022 were analysed in order to discover which new product launches HCPs are discussing as well as #WhatHCPsThink.
  • Mentions of drug approvals by the FDA, EMA, NICE, and CHMP were included in the data, as well as mentions of ‘drug approval’ by HCPs in their Twitter conversations.
  • Between 1 October and 31 October 2022, there were 2,527 HCP mentions of new pharmaceutical product launches and drug approvals from 1,830 unique HCP authors from around the world. 

Click here to read the latest article

View all articles >

Meet the Authors

Paul Cranston

Paul analyses the online conversations of HCPs to provide insights for pharmaceutical companies about what HCPs think. With a background in international development, he is passionate about using data to reveal the unmet needs in healthcare communities.

In his free time, Paul can often be found either writing songs on his guitar or kicking a ball around on a football field.

Tomi Shobande

Tomi is passionate about building relationships with clients and helping them attain their business goals and objectives. With a background in law, international development and human rights, she is keen on bringing about a positive difference around healthcare inequities and shaping health outcomes for all groups.

Tomi enjoys spending good quality time with friends and family. She also is passionate about travel and learning different cultures and histories along the way.

Suggested next

05.09.2022 | Article

Respiratory tracker: Climate crisis = Health crisis, HCPs share their opinions at ERS 2022

The most shared post was on the dangers of misinformation and why context is important

By Mark Sullivan

#WhatHCPsThink About Virtual Congress

18.06.2020 | Article

#WhatHCPsThink About Virtual Congress

#WhatHCPsThink About Virtual Congress

By Lara Meyer

View all articles >